氯维地平与尼卡地平用于出血性卒中急性降压的比较
这项单中心回顾性观察性队列研究纳入2015年1月1日至2020年12月31日成人出血性卒中患者89例(尼卡地平60例、氯维地平29例),比较两种静脉降压药达到目标收缩压的时间。主要终点达标时间在非匹配队列(30 vs 45 min,p=0.73)和倾向评分匹配队列(30 vs 45 min,p=0.47)均无显著差异,多因素线性回归中潜在混杂因素不影响结果。尼卡地平组总输注量更高(1410 vs 330 mL,p<0.0001)但费用显著更低($99.6 vs $497.4,p<0.0001),反跳性高血压(40% vs 75.9%,p=0.0017)和心动过缓(23.3% vs 44.8%,p=0.05)更少。作者认为尼卡地平降压疗效与氯维地平相似,且可能减少反跳性高血压和药物费用,但该回顾性研究检验效能不足,需进一步前瞻性研究确认。
要点
- 出血性卒中患者中,尼卡地平与氯维地平达到目标收缩压时间无显著差异:非匹配队列30 vs 45 min(p=0.73),倾向评分匹配队列30 vs 45 min(p=0.47)。
- 尼卡地平组总输注量高于氯维地平组(1410 vs 330 mL,p<0.0001),但费用显著更低($99.6 vs $497.4,p<0.0001)。
- 尼卡地平组反跳性高血压(40% vs 75.9%,p=0.0017)和心动过缓(23.3% vs 44.8%,p=0.05)均少于氯维地平组。
- 两组在需追加降压药、达标时间百分比、全因死亡率、30天再入院、再出血、血肿扩大、ICU住院时长和住院时长方面无显著差异。
- 低血压、严重低血压、心动过速和急性肾损伤发生率两组无显著差异。
适用人群与场景
- 成人出血性卒中患者,2015年1月1日至2020年12月31日期间接受氯维地平或尼卡地平治疗。
- 排除:创伤相关出血、同时使用持续静脉降压药、研究药物使用持续时间不足1小时、两种药物之间洗脱期不足24小时、需要任何透析、妊娠、被监禁者。
研究设计与关键结果
- 单中心回顾性观察性队列研究,纳入89例出血性卒中患者,尼卡地平组60例、氯维地平组29例。
- 主要终点达到目标收缩压时间:非匹配队列尼卡地平30 min vs 氯维地平45 min(p=0.73);倾向评分匹配队列尼卡地平30 min vs 氯维地平45 min(p=0.47)。
- 多因素线性回归显示潜在混杂因素不影响结果。
- 尼卡地平组总输注量1410 mL vs 氯维地平组330 mL(p<0.0001),但费用$99.6 vs $497.4(p<0.0001)。
- 需追加降压药、达标时间百分比、全因死亡率、30天再入院、再出血、血肿扩大、ICU住院时长和住院时长两组无显著差异。
- 尼卡地平组反跳性高血压40% vs 氯维地平组75.9%(p=0.0017),心动过缓23.3% vs 44.8%(p=0.05)。
- 低血压、严重低血压、心动过速和急性肾损伤两组无显著差异。
证据类型、等级与局限
- 证据类型:单中心回顾性观察性队列研究。
- 局限:原文报告该回顾性研究检验效能不足(underpowered),可能限制其推论;需进一步前瞻性研究确认这些结果。
对床旁实践的改变
- 作者认为,在出血性卒中患者中,尼卡地平降低收缩压的疗效与氯维地平相似,且更可能减少反跳性高血压和药物费用。
- 作者指出该回顾性研究检验效能不足,可能限制这些推论,需进一步前瞻性研究确认。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Intracranial hemorrhage is associated with high mortality and morbidity. Lowering systolic blood pressure (SBP) with an intravenous antihypertensive, such as nicardipine or clevidipine, may reduce the risk of hematoma expansion and rebleeding. Previous studies comparing nicardipine and clevidipine in patients with stroke found no significant difference in blood pressure management. The inclusion of patients with ischemic stroke limited those studies because of convoluted results related to faster door-to-needle times. The purpose of this study was to compare clevidipine with nicardipine in time to goal SBP in hemorrhagic stroke.
METHODS: This single-center retrospective observational cohort study evaluated adult hemorrhagic patients with stroke who received clevidipine or nicardipine from January 1, 2015, to December 31, 2020. Patients were excluded if they had trauma-related hemorrhage, received concurrent continuous intravenous antihypertensives, received the study drug for less than 1-h duration, had a less than 24-h washout period between agents, required any dialysis, were pregnant, or were incarcerated. The primary outcome was time to goal SBP. Secondary outcomes included need for additional antihypertensives, percentage of time at goal SBP, all-cause mortality, 30-day readmission, rebleeding, total volume of antihypertensive infusion, hematoma expansion, intensive care unit length of stay (LOS), hospital LOS, and cost of infusion. Safety outcomes included hypotension, severe hypotension, rebound hypertension, bradycardia, tachycardia, onset of atrial fibrillation, and acute kidney injury.
RESULTS: Of 89 patients included in this study, 60 received nicardipine and 29 received clevidipine. There was no significant difference between nicardipine and clevidipine in time to goal SBP in the unmatched cohort (30 vs. 45 min; p = 0.73) or the propensity-score-matched cohort (30 vs. 45 min; p = 0.47). Results were not affected by potential confounders in the multiple linear regression. The nicardipine group had a higher total volume from infusion compared with the clevidipine group (1410 vs. 330 mL; p < 0.0001) but significantly lower cost ($99.6 vs. $497.4; p < 0.0001). There were no significant differences in need for additional antihypertensives, percentage of time at goal SBP, all-cause mortality, 30-day readmission, rebleeding, hematoma expansion, intensive care unit LOS, and hospital LOS. Compared with the clevidipine group, the nicardipine group had less rebound hypertension (40% vs. 75.9%; p = 0.0017) and less bradycardia (23.3% vs. 44.8%; p = 0.05). There were no significant differences in hypotension, severe hypotension, tachycardia, and acute kidney injury.
CONCLUSIONS: In patients with hemorrhagic stroke, nicardipine appeared to have similar efficacy as clevidipine in SBP reduction, with a more likely reduction of rebound hypertension and drug cost. This retrospective study was underpowered, which may limit these implications. Further prospective studies are warranted to confirm these results.
参考来源
- Saldana S, Breslin J, Hanify J, et al. Comparison of Clevidipine and Nicardipine for Acute Blood Pressure Reduction in Hemorrhagic Stroke. Neurocrit Care. 2021. PMID: 34904214. doi:10.1007/s12028-021-01407-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。